• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Anti-fibrotic Drug Discovery

Anti-fibrotic Drug Discovery

9781788015103
1 064,70 zł
958,23 zł Zniżka 106,47 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 958,23 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
Szczegóły produktu
82207
9781788015103
9781788015103

Opis

Rok wydania
2020
Numer wydania
1
Oprawa
twarda
Liczba stron
356
Wymiary (mm)
156.00 x 234.00
  • TGFß Signalling in Fibrosis; Targeting Integrins in Fibroproliferative Disease; Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor (FXR) Activators; Autotaxin Inhibitors in Fibrosis; Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes:: Intervention at the Core of Fibrotic Pathology; Galectin-3 Involvement in Fibrotic Diseases; The Emerging Role of CXCR4 in IPF; BH3 Mimetic Drugs for Anti-Fibrotic Therapy; Intratumoral Fibrosis:: Emerging Concepts and Therapeutic Opportunities; Targeting Fibroblasts in Cancer and Fibrosis
Komentarze (0)